Frederick Beddingfield, III, MD, PhD, FAAD, FACMS

Dr. Beddingfield is a physician-scientist and biotech entrepreneur. He is currently CEO and Board Director of Rubedo Life Sciences. He also serves as Chairman of the Board of Sagesse Bio and as a director of Cytrellis Biosystems.

Previously he was an Executive Partner at Apollo Health Ventures, a longevity and age-related disease fund. He served as CEO and director of Kira Pharmaceuticals developing biologics for immunology, inflammation, and rare diseases from 2020 to 2023. He was founder, president, chief executive and member of the board of directors of Sienna Biopharmaceuticals Inc. and took the company public in 2017. Previously he served as Chief Medical Officer of Kythera Biopharmaceuticals, acquired by Allergan in 2015. He has led the development and approvals of global leading brands in medical dermatology, aesthetics, neurology, metabolic, and other therapeutic areas. These brands include Botox, Juvederm, Voluma, Kybella, Latisse, Aczone, and Tazorac.

Since completing his training, Frederick has maintained a clinical and teaching practice at UCLA. He is a board-certified dermatologist and emergency medicine physician and fellowship trained in dermatologic surgery and cutaneous oncology. Frederick completed his medical degree with honors at UNC Chapel Hill, his residency and fellowship training at UCLA, and his PhD in Policy Analysis Research at RAND. He serves on the medical advisory board of the Children’s Skin Disease Foundation and Camp Wonder. He is co-founder of the Dermatology Summit and Dermatology Innovation Forum conferences, and a Board Trustee of Advancing Innovation in Dermatology.